Table 2.
Univariate and multivariate logistic regression analysis of LAT/SEC presence based on peri-procedural data in the training cohort.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95%CI) | P-value | OR (95%CI) | P-value | |
| Age, years | 1.03 (1.02–1.05) | <0.001 | 1.04 (1.02–1.06) | 0.001 |
| Male sex | 0.95 (0.72–1.27) | 0.748 | ||
| Medical history | ||||
| HTN | 1.68 (1.25–2.27) | 0.001 | 1.44 (1.02–2.06) | 0.041 |
| T2DM | 1.13 (0.82–1.54) | 0.445 | ||
| Previous stroke/TIA | 1.94 (1.41–2.65) | <0.001 | 1.79 (1.23–2.60) | 0.002 |
| Vascular disease | 1.93 (0.95–3.74) | 0.058 | ||
| Non-paroxysmal AF | 3.58 (2.7–4.77) | <0.001 | 2.76 (1.99–3.85) | 0.001 |
| CAD | 1.34 (1.01–1.78) | 0.042 | ||
| laboratory data | ||||
| eGFR, ml/(min 1.73 m2) | 0.99 (0.98–0.99) | <0.001 | ||
| Uric acid, μmol/L | 1.02 (1.01–1.04) | 0.028 | ||
| PT-INR | 1.5 (1.17–1.91) | 0.001 | ||
| Echocardiographic parameters | ||||
| LAD, mm | 1.27 (1.23–1.32) | <0.001 | 1.21 (1.16–1.26) | 0.001 |
| LVEDD, mm | 1.09 (1.06–1.13) | <0.001 | ||
| LVEF, % | 0.89 (0.86–0.91) | <0.001 | 0.92 (0.89–0.94) | 0.001 |
| Medication | ||||
| Statin | 1.05 (0.79–1.39) | 0.754 | ||
| Amiodarone | 1.21 (0.88–1.67) | 0.24 | ||
| Antiplatelet | 1.02 (0.75–1.36) | 0.918 | ||
CAD, coronary artery disease; HTN, Hypertension; LAD, left atrium diameter; LAT, left atrial thrombus; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; SEC, spontaneous echo contrast; T2DM, Type 2 diabetes mellitus; TIA, transient ischemic attack.